People who use it are greatly at risk for [[meningococcal infections]] and it is only be prescribed to those who have enrolled in and follow a [[risk evaluation and mitigation strategy]], which involves doctors counseling people to whom they are prescribing the drug, giving them educational materials, and ensuring that they are vaccinated, all of which must be documented.<ref name=USlabel2017>{{cite web|title=Eculizumab label|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125166s417lbl.pdf|publisher=FDA|date=January 2017}} For label updates, see [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125166 FDA index page for BLA 125166]</ref><ref name=UKlabel2017>{{cite web|title=Soliris - Summary of Product Characteristics|url=https://www.medicines.org.uk/emc/medicine/19966|publisher=UK Electronic Medicines Compendium|accessdate=18 July 2017|language=en|date=23 March 2017}}</ref> It is administered in a clinic by intravenous infusion.

 

